...
首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >l l ‐3,4‐dihydroxyphenylalanine ( l l ‐DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha‐synuclein mouse models of Parkinson's disease
【24h】

l l ‐3,4‐dihydroxyphenylalanine ( l l ‐DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha‐synuclein mouse models of Parkinson's disease

机译:L-3,4-二羟基苯基丙氨酸(L L L L L L L L L L L L L L L L L L L L L-DoPaminergericeCeneration和Motor功能障碍在铁过载和突变体α-突触核蛋白模型的帕金森病

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Treatment with the dopamine ( DA ) precursor l ‐3,4‐dihydroxyphenylalanine ( l ‐ DOPA ) provides symptomatic relief arising from DA denervation in Parkinson's disease. Mounting evidence that DA autooxidation to neurotoxic quinones is involved in Parkinson's disease pathogenesis has raised concern about potentiation of oxidative stress by l ‐ DOPA . The rate of DA quinone formation increases in the presence of excess redox‐active iron (Fe), which is a pathological hallmark of Parkinson's disease. Conversely, l ‐ DOPA has pH ‐dependent Fe‐chelating properties, and may act to ‘redox silence’ Fe and partially allay DA autoxidation. We examined the effects of l ‐ DOPA in three murine models of parkinsonian neurodegeneration: early‐life Fe overexposure in wild‐type mice, transgenic human (h)A53T mutant α‐synuclein (α‐syn) over‐expression, and a combined ‘multi‐hit’ model of Fe‐overload in hA 53T mice. We found that l ‐ DOPA was neuroprotective and prevented age‐related Fe accumulation in the substantia nigra pars compacta ( SN c), similar to the mild‐affinity Fe chelator clioquinol. Chronic l ‐ DOPA treatment showed no evidence of increased oxidative stress in wild‐type midbrain and normalized motor performance, when excess Fe was present. Similarly, l ‐ DOPA also did not exacerbate protein oxidation levels in hA 53T mice, with or without excess nigral Fe, and showed evidence of neuroprotection. The effects of l ‐ DOPA in Fe‐fed hA 53T mice were somewhat muted, suggesting that Fe‐chelation alone is insufficient to attenuate neuron loss in an animal model also recapitulating altered DA metabolism. In summary, we found no evidence in any of our model systems that l ‐ DOPA treatment accentuated neurodegeneration, suggesting DA replacement therapy does not contribute to oxidative stress in the Parkinson's disease brain.
机译:摘要用多巴胺(DA)前体L-3,4-二羟基苯丙氨酸(L - DOPA)对帕金森病中的Da Denervation产生的症状浮雕。达自动氧化对神经毒性醌的安装证据涉及帕金森病的发病机制提出了L - DOPA对氧化应激的增强的担忧。在过量的氧化还原活性铁(Fe)存在下,Da醌形成的速率增加,这是帕金森病的病理标志。相反,L - DOPA具有pH相依赖的FE螯合性能,并且可以采取“氧化还原沉默”Fe和部分allay da自动氧化。我们检查了L - DOPA在帕金森神经变性的三个小鼠模型中的影响:野生型小鼠的早期Fe过量曝光,转基因人(H)A53T突变体α-突触核蛋白(α-SYN)过表达,以及组合' HA 53T小鼠中的Fe-Overload模型。我们发现L - DOPA是神经保护和预防患者中与患者的死亡Fe积累,类似于轻度亲和Fe Chelator Clioquinol。慢性L - DOPA治疗表明,当存在过量的Fe时,没有伴有野生型中脑中氧化应激和标准化的电动机性能增加的证据。类似地,L - DOPA也没有加剧HA 53T小鼠的蛋白质氧化水平,有或没有过量的终峰Fe,并且显示出神经保护的证据。 L - DOPA在Fe-Fed HA 53T小鼠中的影响有些静音,表明单独的Fe-Chelation不足以减弱动物模型中的神经元损失,也重新承诺改变改变的DA代谢。总之,我们发现我们的模型系统中没有任何证据,其中L - DOPA治疗突出的神经变性,表明DA替代疗法在帕金森病的脑中没有导致氧化胁迫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号